Neuland Labs.
Drug Manufacturers - Specialty & Generic · NEULANDLAB
Mid CapHealthcareHigh Growth
Davuluri Saharsh Rao
Vice-Chairman & Managing Director · Visionary
Company DNA
Innovation-Led
About
Neuland Labs. is a Mid Cap company in the Healthcare sector, listed on NSE as NEULANDLAB. With a market cap of ₹16K Cr and revenue of ₹1K Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Research-heavy pharmaceutical focus requires a culture centered on scientific exploration and product development agility. Its strategic mandate: Sustaining growth in the complex CDMO space necessitates shifting toward high-margin proprietary molecules and R&D capability.
FAQ
What kind of company is Neuland Labs.?
Neuland Labs. is a Mid Cap Healthcare company (NEULANDLAB) in the High Growth phase with a market cap of ₹16K Cr. It is classified as Innovation-Led in culture.
What is Neuland Labs.'s culture and work environment like?
Neuland Labs. has a Innovation-Led culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Research-heavy pharmaceutical focus requires a culture centered on scientific exploration and product development agility.
Who leads Neuland Labs.?
Neuland Labs. is led by Davuluri Saharsh Rao (Vice-Chairman & Managing Director), a Visionary leader with 22 years of experience.
What are Neuland Labs.'s financials?
Neuland Labs. reported revenue of ₹1K Cr in FY25 with a 5-year revenue CAGR of 15.8%. Operating margin: 18.6%. Market cap: ₹16K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
Research-heavy pharmaceutical focus requires a culture centered on scientific exploration and product development agility.
Mandate
Sustaining growth in the complex CDMO space necessitates shifting toward high-margin proprietary molecules and R&D capability.
Sustaining growth in the complex CDMO space necessitates shifting toward high-margin proprietary molecules and R&D capability.
Financials
Revenue FY25₹1K Cr
PAT FY25₹260 Cr
Rev CAGR 5Y15.8%
OPM18.6%
NPM18.1%
ROE17.1%
ROCE15.6%
P/E87
Fwd P/E35.9
P/B9.6
D/E16.3
Mkt Cap₹16K Cr
Promoter38%
Institutional26.5%
Similar Culture
Could You Lead Neuland Labs.?
Take the Genome Benchmark →